SpyBiotech Hires Dr. Prakash Bhuyan as CMO

OXFORD, England & CAMBRIDGE, Mass. — SpyBiotech, a biotechnology firm specializing in innovative vaccine technologies, has announced the appointment of Dr. Prakash Bhuyan as its new Chief Medical Officer. Dr. Bhuyan brings extensive experience from his previous leadership roles in vaccines and biologics at Pfizer and Merck, where he played a crucial role in the development of significant vaccines, including Trumenba™ and Vaxelis™. Dr. Bhuyan holds an MD and PhD in Immunology from the University of Texas Southwestern Medical Center, along with a specialization in Internal Medicine from Emory University and a sub-specialization in Infectious Disease from the University of Pennsylvania. His expertise is expected to enhance SpyBiotech's capabilities in addressing various medical challenges. In his statement, Dr. Bhuyan expressed enthusiasm about joining SpyBiotech at a critical juncture, highlighting the company's collaboration with the University of Oxford and the advancement of its Phase I HCMV vaccine trial. He emphasized that these developments position SpyBiotech to tackle significant unmet medical needs effectively. SpyBiotech is recognized for its clinical-stage vaccine platform technologies aimed at combating infectious diseases, cancer, and chronic conditions. The company holds exclusive rights from the University of Oxford to utilize and commercialize its proprietary SpyTag/SpyCatcher technologies, which are pivotal in vaccine development.